The emergency use authorizations (EUAs) of two mRNA-based severe acute respiratory
syndrome coronavirus (SARS-CoV)-2 vaccines approximately 11 months after publication of …

The therapeutic use of messenger RNA (mRNA) has fueled great hope to combat a wide
range of incurable diseases. Recent rapid advances in biotechnology and molecular …

To date, the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has determined 399,600,607 cases and 5,757,562 …

The field of cancer nanomedicine seeks to overcome the inherent shortcomings of
conventional cancer diagnostics and therapies. Yet despite the surge of interest in and …

The growing understanding of RNA functions and their crucial roles in diseases promotes
the application of various RNAs to selectively function on hitherto “undruggable” proteins …

Due to the fact that mRNA technology allows the production of diverse vaccines and
treatments in a shorter time frame and with reduced expense compared to conventional …

Background Vaccines are critical cost-effective tools to control the coronavirus disease 2019
(COVID-19) pandemic. However, the emergence of variants of the severe acute respiratory …

The increasing number of approved nucleic acid therapeutics demonstrates the potential to
treat diseases by targeting their genetic blueprints in vivo. Conventional treatments …

Messenger RNA (mRNA) has emerged as a new category of therapeutic agent to prevent
and treat various diseases. To function in vivo, mRNA requires safe, effective and stable …

The germinal centre (GC) response is critical for the generation of affinity-matured plasma
cells and memory B cells capable of mediating long-term protective immunity …